Antivenom

North American pit viper envenomation causes cytotoxic tissue injury, venom-induced coagulopathy, and occasional neuromuscular toxicity. In current U.S. practice, the key antivenom decision is usually CroFab versus Anavip, but earlier antivenom matters more than chasing a specific product.

Choosing Between U.S. Antivenoms

• Two antivenom options: U.S. hospitals now use two crotalid antivenoms: CroFab, an ovine Fab product, and Anavip, an equine F(ab)2 product with different pharmacology and practical strengths.
• Source venom differences: CroFab is raised against four U.S. native snake venoms, while Anavip uses Bothrops asper and Middle American rattlesnake venom, a detail that helps explain their different performance profiles.
• Half-life advantage: Anavip has a longer half-life, which makes it better at preventing recurrent coagulopathy after rattlesnake envenomation. We get into how that bedside distinction matters in the episode.
• Whole-venom neutralization: CroFab appears better at neutralizing whole venom in preclinical data, a physiologic reason it may have an edge when local tissue injury is the dominant problem.
• Practical product choice: If tissue damage predominates, CroFab may be favored; if coagulopathy predominates, Anavip may be favored, but stocked availability should not delay treatment.

Assessing Pit Viper Envenomation

• Three toxicity domains: Snake envenomation is best framed in three buckets: cytotoxic tissue damage, hematologic toxicity, and neuromuscular effects, each of which changes urgency and follow-up.
• Tissue injury pattern: Cytotoxic venom causes severe edema, ecchymosis, and hemorrhagic bullae, with swelling that can cross joints and threaten function if treatment is delayed.
• Consumptive coagulopathy clues: Venom-induced consumptive coagulopathy often looks like DIC without the shower emboli, and toxicology consultants will usually want the platelet count, INR, and fibrinogen up front.
• Thrombocytopenia phenotype: Venom can produce venom-induced thrombocytopenia through platelet dysfunction and destruction, a separate hematologic pattern from fibrinogen depletion.
• Neuromuscular red flags: Paresthesias may be the early clue, while severe envenomation can progress to respiratory depression. We cover the red-flag trajectory on the show.

What the Evidence Supports

• CroFab tissue data: A randomized trial in copperhead bites found CroFab improved functional recovery at 14 days versus placebo, though that advantage was not seen by 28 days.
• Anavip coagulopathy data: A multicenter randomized trial found Anavip reduced recurrent coagulopathy better than Fab antivenom, the finding that largely drove its U.S. adoption.
• Copperhead subgroup signal: A post hoc copperhead analysis found no meaningful difference in antivenom use between CroFab and Anavip, suggesting similar effectiveness for tissue-focused presentations.
• Evidence gap caveat: No trial has specifically established Anavip as superior for tissue injury, so confidence is stronger for its coagulopathy benefit than for local wound outcomes.
• Time over brand preference: The biggest management pearl is not to transfer solely for one antivenom brand; faster antivenom administration matters more than product matching.

References:

1. Sánchez EE, et al. The efficacy of two antivenoms against the venom of North American snakes. Toxicon. 2003 Mar 1;41(3):357-65. PMID: 12565759.
2. Gerardo CJ, et al. The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery From Copperhead Snake Envenomation: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Ann Emerg Med. 2017 Aug;70(2):233-244.e3. PMID: 28601268.
3. Bush SP, et al. Comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial. Clin Toxicol (Phila). 2015 Jan;53(1):37-45. PMID: 25361165
4. Gerardo CJ, et al. Control of venom-induced tissue injury in copperhead snakebite patients: a post hoc sub-group analysis of a clinical trial comparing F(ab')2 to Fab antivenom. Clin Toxicol (Phila). 2022 Apr;60(4):521-52. PMID: 34590543.